NCT06430905View on ClinicalTrials.gov

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
BIOLOGICAL

HB-502 and HB-501 alternating 2-vector therapy Dose Level 1

Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.

BIOLOGICAL

HB-502 and HB-501 alternating 2-vector therapy Dose Level 2

Administration of HB-502 and HB-501 alternating 2-vector therapy to 10 participants.

OTHER

Placebo

Administration of placebo to 5 participants.

Trial Locations (5)

19104

Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia

30030

The Hope Clinic at Emory University, Decatur

32803

Orlando Immunology Center (OIC), Orlando

02115

Brigham and Women´s Hospital, Boston

02215

Beth Israel Deaconness Medical Center (BIDMC), Boston

Sponsors
All Listed Sponsors
lead

Hookipa Biotech GmbH

INDUSTRY

NCT06430905 - Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART | Biotech Hunter | Biotech Hunter